DEF: Tandem Diabetes Care Sets May 20, 2026 Annual Meeting

Tandem Diabetes Care, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026, detailing proposals for director elections, executive compensation, and plan amendments.

Summary

• Tandem Diabetes Care, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on May 20, 2026, at 3:00 p.m. Pacific Time.
• The meeting agenda includes the election of nine directors, an advisory vote on executive compensation, approval of the amended 2023 Long-Term Incentive Plan to increase authorized shares, amendments to the Certificate of Incorporation regarding director removal and officer liability, and ratification of Ernst & Young LLP as the independent auditor.
• The company highlights 2025 business achievements, including surpassing $1 billion in worldwide sales, a 5% increase in worldwide pump shipments to over 126,000 units, FDA clearance of Control-IQ+ technology for type 2 diabetes, and global rollout of t:slim X2 pump integration with Abbott's FreeStyle Libre 3 Plus CGM.
• Executive compensation for 2025 focused on a pay-for-performance philosophy, with base salary increases ranging from 3% to 8%, and cash bonuses awarded at 87% of target based on company performance.
• The company is seeking stockholder approval to increase the number of shares authorized under its 2023 Long-Term Incentive Plan by 3,260,000 shares to continue incentivizing employees.
• Amendments to the Certificate of Incorporation are proposed to allow director removal with or without cause and to limit officer liability to the maximum extent permitted by law.
• Ernst & Young LLP has served as the company's independent auditor since 2009, with audit fees for 2025 totaling $2,424,150.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong 2025 financial performance and strategic advancements, though the need for additional shares under the incentive plan and the partial miss on the revenue target for bonuses temper the outlook slightly.

Positives

• Surpassed $1 billion in worldwide sales for 2025.
• Grew annual worldwide pump shipments by 5% to over 126,000 units.
• Received FDA clearance for Control-IQ+ technology for people with type 2 diabetes.
• Launched global commercial rollout of t:slim X2 pump integration with Abbott's FreeStyle Libre 3 Plus CGM.
• Initiated launch of Android mobile control for the Tandem Mobi insulin delivery system.
• Achieved positive free cash flow in the third and fourth quarters of 2025.
• Expanded year-over-year gross margin to 54%, with a record quarterly margin of 58% in Q4 2025.
• Generated a positive operating margin of 3% in Q4 2025, a 15 percentage point improvement year-over-year.

Negatives

• The company's 2025 worldwide revenue target of $1.054B was not fully met, with actual achievement at 81% of target, impacting the financial performance objective payout for the short-term cash incentive program.
• Performance Stock Units (PSUs) granted in early 2023, measured against targeted revenue CAGR and Total Shareholder Return (TSR) relative to the Russell 3000 index, were forfeited as neither target was achieved.

Risks

• The filing mentions that forward-looking statements are subject to risks, uncertainties, and other factors described in the company's Annual Report on Form 10-K, and actual results could differ materially.
• The company is continuing to assess and respond to operational and commercial risks related to business growth, intensifying competition, and global macroeconomic conditions.
• The 2023 Long-Term Incentive Plan's share reserve duration is highly dependent on changes in the stock price.

Future Outlook

The company's 2025 business highlights and strategic initiatives, including commercial operations modernization, new technology delivery, and business model reshaping, are expected to lay a strong foundation for future sustainable growth and profitability. The proposed increase in shares for the Long-Term Incentive Plan aims to continue motivating employees and aligning interests with stockholders.

Management Comments

• "When designing our 2025 executive compensation program, our Compensation Committee considered a number of factors, including the business objectives established at the beginning of 2025, the 2025 budget approved by our board of directors, and the intense competition for talent within the medical device and technology industries."
• "Effective in 2025, the benchmark target for total executive compensation was reduced to the 50th percentile from the 60th percentile of our peer group, based on the continued maturation of our compensation practices in alignment with company growth and shareholder feedback."
• "Our product development achievements in 2025, include but are not limited to commercial milestones relating to Control-IQ+ technology, t:slim integration with FreeStyle Libre 3 Plus, and Android control for Tandem Mobi, along with other web and app based offerings."
• "Together, the progress we made against our key initiatives in 2025 were transformational for our company and set a strong foundation for Tandem to drive sustainable growth and profitability."

Industry Context

StockSavvy.ai notes that Tandem Diabetes Care's focus on expanding its product integrations (e.g., with Abbott's FreeStyle Libre 3 Plus) and developing new technologies like Android mobile control for Tandem Mobi aligns with broader industry trends in the diabetes management sector, which emphasizes connected devices and user-friendly interfaces. The company's push into pharmacy benefit channels also reflects a strategic move to improve customer access and potentially reduce costs, a common objective in the healthcare industry.

Comparison to Industry Standards

• The company's 2025 peer group, used for compensation benchmarking, includes companies like Dexcom, Insulet, and Abbott, which are significant players in the diabetes care and medical device industries.
• The proposed increase of 3,260,000 shares for the 2023 Long-Term Incentive Plan was evaluated by the board with input from compensation consultants (WTW) and proxy advisory services to ensure it is within industry standards.
• The company's burn rate for equity incentive plans in 2025 was 3.1%, which is a key metric compared against industry norms for companies of similar size and growth stage.

Corporate Governance

Legal Proceedings

• The filing notes that there are no legal proceedings related to any directors, director nominees, or executive officers that require disclosure under Item 401(f) of Regulation S-K.
• During the year ended December 31, 2025, each of the company's executive officers filed one late Form 4 on June 5, 2026, relating to one equity award granted on May 30, 2026.
• The Form 3 for Sandra Beaver, appointed to the board on November 7, 2025, was filed on November 25, 2025.

Related Party Transactions

• John Sheridan (President and CEO) and Leigh Vosseller (EVP, CFO, Treasurer) are in a personal relationship and share a primary residence. Ms. Vosseller reports directly to Mr. Sheridan. The company has implemented additional internal controls and procedures, and compensation decisions for each other are handled by the Compensation Committee.
• Christopher Twomey (Director) is the brother-in-law of an employee who is a manufacturing engineer. Mr. Twomey does not serve on the compensation committee and is not involved in decisions regarding this employee's compensation. The employee's compensation is commensurate with similar roles.

Stakeholder Impact

• Shareholders: The proposed increase in authorized shares for the Long-Term Incentive Plan could lead to dilution, but is intended to align executive and shareholder interests. The election of directors and advisory vote on compensation directly involve shareholder governance.
• Employees: The Long-Term Incentive Plan aims to attract, retain, and motivate employees, including executive officers, through equity awards. Changes in compensation practices and the proposed officer liability limits may impact employee morale and retention.
• Management: Executive compensation is tied to performance, with base salary increases and cash bonuses reflecting company achievements. Proposed amendments to officer liability could reduce personal risk for executives.
• Auditors: The ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 continues an established relationship.

Next Steps

• Stockholders are encouraged to submit their proxy or voting instructions as soon as possible.
• The company will announce voting results in a Form 8-K filing within four business days following the Annual Meeting.
• The company plans to drive utilization of pharmacy benefits for all customers in 2026.
• The company plans for Ms. Beaver to succeed Mr. Twomey as audit committee chair in the second half of 2026.

Key Dates

Recommendation

The company has demonstrated strong financial performance in 2025, exceeding $1 billion in sales and showing significant operational improvements. However, the need to increase the equity incentive pool suggests potential dilution, and the partial miss on the revenue target for short-term incentives indicates some execution challenges. While the strategic initiatives are positive, the company is still navigating a competitive landscape. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the impact of the new incentive plan and continued execution against strategic goals.

Keywords

Tandem Diabetes Care, Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Long-Term Incentive Plan, Certificate of Incorporation Amendment, Independent Auditor, Diabetes Technology, Insulin Pump